Jupiter Neurosciences/$JUNS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Jupiter Neurosciences
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
- Ticker
- $JUNS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Jupiter, United States
- Website
- jupiterneurosciences.com
JUNS Metrics
BasicAdvanced
$3.9M
-
-$18.57
-
-
Price and volume
Market cap
$3.9M
52-week high
$11.20
52-week low
$2.25
Average daily volume
72K
Financial strength
Current ratio
0.657
Quick ratio
0.395
Long term debt to equity
-0.56
Total debt to equity
-4.779
Interest coverage (TTM)
-35.95%
Profitability
Gross margin (TTM)
-2,811.53%
Net profit margin (TTM)
-14,220.12%
Operating margin (TTM)
-15,165.07%
Management effectiveness
Return on assets (TTM)
-159.56%
Return on equity (TTM)
-1,888.70%
Valuation
Price to revenue (TTM)
22.853
Price to book
-5.41
Price to tangible book (TTM)
-5.41
Price to free cash flow (TTM)
-0.204
Free cash flow yield (TTM)
-490.36%
Free cash flow per share (TTM)
-14.613
Growth
Earnings per share change (TTM)
33.66%
3-year earnings per share growth (CAGR)
3.04%
JUNS Financial Performance
Revenues and expenses
JUNS Earnings Performance
Company profitability
Upcoming events
No upcoming events
JUNS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.